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Background. The inflammatory marker C-reactive protein
(CRP) has been found in most, but not all, prospective studies
to be associated with future cardiovascular outcomes. However,
CRP has not been tested in the high-cardiovascular risk popu-
lation of type 2 diabetic nephropathy.
Methods. We studied the independent relationship between
CRP and the subsequent development of incident or recur-
rent arteriosclerotic outcomes (primary) and congestive heart
failure events (secondary) in 1560 individuals with diabetic
nephropathy, overt proteinuria, and hypertension enrolled in
the prospective Irbesartan Diabetic Nephropathy Trial.
Results. Traditional cardiac risk factors were highly preva-
lent, CRP levels were high overall [quintiles (mg/L) 1st, 0 to
1.2; 2nd, 1.3 to 2.5; 3rd, 2.6 to 5.0; 4th, 5.1 to 10.0; and 5th,
>10), and subsequent cardiovascular events were very com-
mon. A univariate relationship existed between CRP and total
arteriosclerotic outcomes (P < 0.0001). However, after adjust-
ing for study intervention and traditional risk factors, the rela-
tionship no longer remained. In fact, controlling for previous
cardiovascular disease alone caused the association to become
nonsignificant. The secondary analysis found a significant uni-
variate relationship between CRP and congestive heart failure
events (P = 0.007) that persisted in multivariate analyses (P =
0.006). However, this relationship was confined to the highest
CRP quintile [RR (95% CI) 2.0 (1.27, 3.16)].
Conclusion. In diabetic patients with nephropathy, CRP does
not add predictive information above and beyond that provided
by traditional established risk factors. Whether this holds true
for other populations with similar risk burdens is an important
public health question that should be addressed. A secondary
finding of a link between CRP and congestive heart failure re-
quires further confirmation.
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In recent years the role of inflammation in the ini-
tiation and progression of atherothrombosis has been
intensively studied [1]. Most [2–4], but not all [5], prospec-
tive studies from population-based or selected cohorts
suggest that serum concentrations of the inflammatory
marker C-reactive protein (CRP) are positively associ-
ated with the development of de novo or recurrent ar-
teriosclerotic disease, independent of traditional cardio-
vascular risk factors.
However, there is a paucity of data on the association
between CRP levels and cardiovascular disease outcomes
in chronic kidney disease (CKD) patients and, more
specifically, in individuals with type 2 diabetic nephropa-
thy. Both of these populations are at particularly high risk
for cardiovascular disease events [6, 7].
We hypothesized that baseline concentrations of CRP
are closely associated with the subsequent development
of incident or recurrent arteriosclerotic outcomes, inde-
pendent of traditional risk factors, in high-risk type 2 di-
abetic patients with nephropathy. This hypothesis was
tested in subjects enrolled in the multicenter, interna-
tional Irbesartan Diabetic Nephropathy Trial (IDNT) co-
hort. In addition, we performed a secondary analysis on
congestive heart failure outcomes to confirm a recent
population-based preliminary report that found an asso-
ciation between CRP levels and incident congestive heart
failure [8].
METHODS
Population
The IDNT was an investigator-initiated, prospective,
three-arm, randomized, double-masked study in 1715 pa-
tients with type 2 diabetic nephropathy that compared
treatment with irbesartan, amlodipine, or placebo. Ran-
domization occurred between March 21, 1996, and Febru-
ary 25, 1999 in over 200 clinical centers in North and
South America, Europe, and Asia. Details of the baseline
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patient characteristics and renal and cardiovascular out-
comes of this study have been published [9–11]. The insti-
tutional review board or ethics committee of each center
approved the protocol, and all patients gave written in-
formed consent after reviewing a written summary of the
study plan. In brief, eligibility criteria included the fol-
lowing: age between 30 and 70 years old; type 2 diabetes
mellitus and overt nephropathy as manifested by a 24-
hour urinary protein excretion rate ≥900 mg; a serum
creatinine between 1.0 and 3.0 mg/dL in females or 1.2
and 3.0 mg/dL in males; and baseline blood pressures >
135/85 mm Hg or treatment with antihypertensive agents.
The primary outcome of the IDNT was time to occur-
rence of a composite renal outcome of doubling of entry
serum creatinine, end-stage renal disease (ESRD), or all-
cause cardiovascular mortality. The present study was an
ancillary analysis of the IDNT and included the 91% of
participants in whom samples were available for deter-
mination of baseline serum CRP (N = 1560).
Measurements and laboratory tests
Body mass index (BMI) was defined as weight (kg)
divided by height (m2). Blood pressures were taken
in the seated position using standardized sphygmo-
manometers. Baseline samples were drawn between
March 21, 1996, and February 25, 1999, and stored at
−70◦C. High sensitivity CRP concentrations were mea-
sured in the Vitamin Metabolism and Aging Labora-
tory (USDA-Human Nutrition Research Center, Boston,
MA, USA). CRP concentrations were determined by
a latex particle–enhanced immunoturbidimetric assay
(k-ASSAY) (Kamiya Biomedical Company, Seattle, WA,
USA). The intra- and intercoefficients of variation for
this assay are 2.0% and 2.5%, respectively. CRP quintiles
were defined as the following (mg/L): 1st, 0 to 1.2; 2nd,
1.3 to 2.5; 3rd, 2.6 to 5.0; 4th, 5.1 to 10.0; and 5th, >10.
Serum creatinine, hemoglobin A1c (HbA1c), lipid levels,
and 24-hour urinary protein levels were measured in one
of four IDNT regional laboratories using standard au-
tomated clinical chemistry techniques. Proteinuria mea-
surements were based on the urinary protein/creatinine
ratio derived from the 24-hour urine collection.
Definition of cardiovascular outcomes
The total arteriosclerotic outcome, the primary out-
come for this analysis, included all of the following [9]: car-
diovascular mortality; myocardial infarction documented
by clinical data such as enzyme and electrocardiogram
changes; stroke documented by brain imaging or clinical
deficits persisting more than 24 hours and requiring hos-
pitalization; lower extremity amputations, and unplanned
(at time of randomization) cardiac or peripheral revascu-
larization procedures. All outcomes were ultimately ad-
judicated by an IDNT Outcomes Committee [11]. For
the purposes of this present study we performed a sep-
arate secondary analysis on all congestive heart failure
outcomes, defined as congestive heart failure requiring
hospitalization or, alternatively, treatment with renin-
angiotensin-aldosterone blockade.
Statistical methods
Because the cardiovascular outcomes that we modeled
(total arteriosclerotic and congestive heart failure) could
occur more than once, we determined relative risks using
the Anderson-Gill formulation of the proportional haz-
ards model [12] in which patients are considered at risk for
the first event from randomization to the time of the first
event, at risk for the second event from the day follow-
ing the first event to the time of the second event, and so
forth, permitting use of all of the data. In accordance with
the method of Lee, Wei, and Amato [13] we used a robust
variance estimate that takes into account the possibility of
correlation of risk for multiple events within each patient.
Models were developed that included the randomization
group and the following traditional baseline cardiovascu-
lar characteristics: age, gender, smoking history, history
of previous cardiovascular disease, BMI, seated systolic
and diastolic blood pressure, HbA1c, the inverse of serum
creatinine, and the total/high-density lipoprotein (HDL)
cholesterol ratio. Quintiles of CRP were analyzed as or-
dered factors. The P value of the first order (linear) com-
ponent of the factor was used to test for a linear trend
across the quintiles. For testing correlations between pa-
rameters and baseline characteristics, CRP and 24-hour
urine protein were logarithmically transformed. Statis-
tical analyses were performed and graphics generated
using S-Plus for Windows version 6.2 (Insightful Corp.,
Seattle, WA, USA).
RESULTS
Of the 1715 patients enrolled in the IDNT, 1560 had
samples available for baseline CRP measurements. With
the exception of BMI (30.9 vs. 29.7) (P = 0.01) and 24-
hour urinary protein levels (3.26 g vs. 2.65 g) (P = 0.05),
there were no significant differences between subjects
who did and did not have CRP samples available. The
cohort was comprised mainly of middle-aged males with
a high degree of cardiovascular disease risk. Nearly half
the study subjects had baseline cardiovascular disease,
and most had a history of smoking, obesity, dyslipidemia,
and overt proteinuria (see Table 1). Cardiovascular out-
comes were followed for a mean of 2.6 years, and events
were very common. The total arteriosclerotic outcome
included 486 events in 361 patients, and the congestive
heart failure outcome included 316 events in 205 patients.
Table 2 confirms the well-recognized correlation be-
tween CRP and BMI [14]. In addition, significant, though
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Table 1. Baseline characteristics
Total subjects 1560
Age years 58 ± 8a (54–65)b
Males % 66.4
Baseline cardiovascular disease
History %
45.5
Cigarette smokers %
Never 38.3
Past 42.1
Current ≤16/day 9.5
Current >16/day 7.5
Not available 2.6
Duration of diabetes years 14.7 ± 8.0a (9–20)b
Body mass index kg/m2 30.9 ± 5.8a (26.8–34.2)b
Diastolic blood pressure mm Hg 87 ± 11a (80–94)b
Systolic blood pressure mm Hg 159 ± 20a(145–171)b
Hemoglobin A1c % 8.1 ± 1.7a(6.9–9.1)b
Total/high-density lipoprotein
cholesterol
5.8 ± 2.2a (4.4–6.9)b
24-hour urinary protein g 2.27c (1.26, 4.0)b
Inverse serum creatinine 7.5 × 10−3 ± 2.38 × 10−3a
(1/lmol/L)(1/mg/dL) (5.66 × 10−3 –9.20 × 10−3)b
[0.66 ± 0.21a (0.50–0.77)b]
C-reactive protein mg/L 3.4c (1.6–7.9)b
aMean ± standard deviation; b25th to 75th percentile; cGeometric mean.
Table 2. Correlations between C-reactive protein (CRP) and
baseline characteristics
Characteristics R P valuea
Body mass index 0.31 <0.0001
Hemoglobin A1c 0.11 <0.0001
Total/high-density lipoprotein cholesterol 0.08 0.003
Systolic blood pressure −0.00 NS
Inverse serum creatinine −0.04 NS
Diastolic blood pressure 0.01 NS
Age −0.00 NS
aNS is nonsignificant.
less clinically relevant, associations between CRP and
HbA1c and the cholesterol ratio are also seen. Higher
CRP levels were also manifested in individuals with a his-
tory of cardiovascular disease (yes, 7.0 and no, 4.9) (P=
0.0001) and females (females, 7.0 and males, 5.3) (P=
0.002), though not in persons with a smoking history.
As shown in Table 3, there was a significant univariate
relationship between CRP and total arteriosclerotic out-
comes. Despite the close correlation between adiposity
and CRP, this finding did not change significantly even
after controlling for the presence of obesity (defined as
BMI >30) (data not shown). Results of multivariate anal-
yses are seen in Figure 1 and Table 3. After adjusting for
study randomization and recognized cardiovascular risk
factors, the significant association between CRP and to-
tal arteriosclerotic events no longer remained. The single
most explanatory parameter in this model was the ex-
istence of a prior history of cardiovascular disease [RR
(95% CI) 1.75 (1.39, 2.19)]. In fact, adding this variable
alone to the univariate analysis removed the significance
of CRP in that model. The only other significant correlate
in the total arteriosclerotic outcome model was seated
diastolic blood pressure (per 10 mm Hg increase) [0.86
(0.78, 0.95)]. No interaction between CRP and kidney
function was found, nor was CRP predictive of outcomes
in subjects even after they were divided into quartiles by
kidney function.
The secondary analysis did find a univariate associa-
tion between CRP and congestive heart failure outcomes
(Table 3). Interestingly, this positive relationship re-
mained after adjustment for study randomization and car-
diovascular risk factors, as shown in Table 3 and Figure 2,
though it was confined to the highest quintile. Similar to
the primary outcome, a prior history of cardiovascular
disease was an important predictor of future congestive
heart failure events, as was an abnormal serum creatinine.
CONCLUSION
This is the first study to determine the relationship
between CRP levels and subsequent cardiovascular out-
comes in a representative population with overt diabetic
nephropathy. CRP was not associated with the subse-
quent development of total arteriosclerotic outcomes in
this large, multicenter cohort, independent of the ef-
fects of traditional risk factors. A secondary analysis did
confirm previous preliminary findings of an association
between CRP and subsequent congestive heart disease
events; however, this was restricted to the highest CRP
quintile [8].
Prospective information about the relationship be-
tween CRP and cardiovascular outcomes in CKD and/or
type 2 diabetes is sparse. A positive association was found
between CRP and hospitalizations in a small cohort of in-
dividuals with advanced CKD (N = 66) (20% diabetic)
followed for 1 year [15]. Though 37% of the hospital-
izations were cardiovascular in origin, the relationship
between cardiovascular events and CRP was not specific
addressed. Prospective and case-control studies analyz-
ing this association in diabetic populations have found
mixed results [16–19]. Of note, none of these studies
included subjects with overt diabetic nephropathy (i.e.,
manifesting elevated serum creatinine levels and gross
proteinuria). This distinction is important because man-
ifestations of kidney disease from type 2 diabetes most
likely reflect a more intense or chronic disease exposure,
and hence a higher cardiovascular disease risk.
The acute phase reactant CRP is a marker of sys-
temic inflammation that has been found, in most stud-
ies, to be a reliable and independent predictor of future
primary or secondary cardiovascular events [1–4]. Con-
sequently, CRP measurements have been touted as a po-
tentially useful tool in clinical practice. However, recent
prospective studies have found CRP to play a more mod-
est or even no predictive role above and beyond that of
traditional cardiac risk factors [5, 20]. Our findings are
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Table 3. C-reactive protein (CRP) and cardiovascular event riska
CRP quintilesb
Outcome 1st 2nd 3rd 4th 5th
Primary: Total arteriosclerotic events
Univariate (P = 0.02) 1.0 1.38 1.29 1.31 1.57
[Ref] [1.00, 1.88] [0.95, 1.76] [0.96, 1.78] [1.13, 2.18]
Multivariate (P = 0.38) 1.0 1.22 1.23 1.21 1.23
[Ref] [0.86, 1.72] [0.87, 1.74] [0.84, 1.73] [0.82, 1.85]
Secondary: Congestive heart failure events
Univariate (P < 0.0001) 1.0 1.27 1.35 1.63 2.58
[Ref] [0.81, 1.99] [0.85, 2.15] [1.03, 2.59] [1.66, 4.02]
Multivariate (P = 0.006) 1.0 1.26 1.21 1.30 2.00
[Ref] [0.79, 2.00] [0.73, 2.01] [0.79, 2.14] [1.27, 3.16]
aControlled for study intervention and the following cardiac risk factors: age, gender, systolic and diastolic blood pressure, body mass index, presence of baseline
cardiovascular disease, smoking, total/high-density lipoprotein cholesterol, hemoglobin A1c, and renal function.
bRelative risk [95% CI].
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Fig. 1. C-reactive protein (CRP) and risk of total arteriosclerotic
events. Adjusted for randomization group and the following recognized
cardiovascular risk factors: age, gender, systolic blood pressure, diastolic
blood pressure, body mass index, renal function, prior cardiovascular
history, smoking, lipids, and hemoglobin A1c.
consistent with and extend the findings of these lat-
ter reports. Part of the lack of association may be re-
lated to an overestimation of the relationship between
CRP and cardiovascular events in earlier published
reports, a pattern that is often seen with emerging risk
factors [21]. However, a crucial factor in our cohort is re-
lated to the particular attributes of this study population.
Individuals with overt diabetic nephropathy manifest
multiple cardiovascular risk factors (e.g., CKD, diabetes,
hypertension, obesity, proteinuria) and consequently a
very high cardiovascular rate [11, 22]. In our trial, a large
proportion of participants suffered a de novo or recurrent
cardiovascular event over a relatively modest follow-up
period. Furthermore, as previously mentioned, the length
and severity of exposure to traditional risk factors is sig-
nificantly greater in our cohort compared to other dia-
betic populations in which CRP has been studied (hence
the relatively high baseline CRP levels seen here). Con-
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Fig. 2. C-reactive protein (CRP) and risk of congestive heart gailure.
Adjusted for randomization group and the following recognized car-
diovascular risk factors: age, gender, systolic blood pressure, diastolic
blood pressure, body mass index, renal function, prior cardiovascular
history, smoking, lipids, and Hemoglobin A1c.
sequently, it is likely that any predictive effect of CRP
was simply subsumed by the heavy traditional cardiovas-
cular disease risk burden seen in our study population.
The powerful predictive value of having a prior history
of cardiovascular disease as well as other traditional risk
factors supports this premise. Put another way, the sim-
ple act of enquiring as to whether a study subject had a
prior history of cardiovascular disease was far more pre-
dictive of future events than was a CRP level. This raises
the question of whether CRP is an effective predictive
tool in any population with a similarly high prevalence of
traditional cardiovascular risk factors. Given the burden
to patients (and the health care system) of using CRP
as a standard predictor of cardiovascular risk, this issue
has important public health implications. Finally, nontra-
ditional risk factors linked to a reduction in the glomeru-
lar filtration rate but not to elevated CRP levels, such as
hyperhomocysteinemia [23], may differentiate our study
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cohort’s risk from individuals with normal kidney func-
tion [24].
Of note, other factors sometimes found to modify
CRP levels and/or cardiovascular risk, such as exercise
and medications like 3-hydroxy-3-methylglutaryl coen-
zymeA (HMG-CoA) reductase inhibitors, were not in-
cluded in this analysis [25, 26]. However, these risk factors
are not “traditional” risk factors, and have not, in general,
been routinely measured in other major prospective CRP
studies. Certainly the former variable would be difficult to
assess routinely in the clinical setting. The lack of associa-
tion between CRP and arteriosclerotic outcomes should
not be related to the length of patient follow-up, since
data suggest that this relationship becomes weaker, not
stronger, over time [21].
A secondary analysis did confirm an earlier finding
in the Framingham population-based cohort that linked
baseline CRP levels with future congestive heart fail-
ure events [8]. Proinflammatory cytokines have been
shown to have modulating effects on left ventricular
function and remodeling, as well as to alter myocyte
function and apoptosis [27]. However, this association
was confined to the uppermost distribution of CRP
and therefore requires further confirmation in other
studies.
In conclusion, our study of high-risk type 2 diabetic
patients with overt nephropathy found that CRP does
not add predictive information about arteriosclerotic risk
above and beyond that provided by established and tra-
ditional risk factors. Whether this is true in other popu-
lations with similar risk burdens is an important public
health question that needs to be addressed. A secondary
finding linking CRP at the highest levels and conges-
tive heart failure events is intriguing but requires further
confirmation.
ACKNOWLEDGMENTS
Support was provided by the United States Department of Agri-
culture, under agreement 581950-9-001. Any opinions, findings, con-
clusions, or recommendations expressed in this publication are those
of the authors and do not necessarily reflect the view of the United
States Department of Agriculture. The Irbesartan Diabetic Nephropa-
thy Trial was supported by grants from Bristol-Myers Squibb and Sanofi-
Synthelabo. The main funding for this research effort was provided by
RO1 HL 67695-02, awarded to Dr. Bostom. There are no potential
conflicts of interest.
Reprint requests to Allon N. Friedman, M.D., Division of Nephrol-
ogy, Indiana University School of Medicine, 1481 W. 10th St.-111N,
Indianapolis, IN 46202.
E-mail: allfried@iupui.edu
REFERENCES
1. WILLERSON JT, RIDKER PM: Inflammation as a cardiovascular risk
factor. Circulation 109 (Suppl 1):S2–S10, 2004
2. RIDKER PM, CUSHMAN M, STAMPFER MJ, et al: Inflammation, aspirin,
and the risk of cardiovascular disease in apparently healthy men. N
Engl J Med 336:973–979, 1997
3. RIDKER PM, BURING JE, SHIH J, et al: Prospective study of C-reactive
protein and the risk of future cardiovascular events among appar-
ently healthy women. Circulation 98:731–733, 1998
4. RIDKER PM, RIFAI N, PFEFFER MA, et al: Inflammation, pravastatin,
and the risk of coronary events after myocardial infarction in pa-
tients with average cholesterol levels. Cholesterol and Recurrent
Events (CARE) Investigators. Circulation 98:839–844, 1998
5. VAN DER MEER IM, DE MAAT MP, KILIAAN AJ, et al: The value of
C-reactive protein in cardiovascular risk prediction: The Rotterdam
Study. Arch Intern Med 163:1323–1328, 2003
6. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC, et al: Kidney disease as
a risk factor for development of cardiovascular disease: A state-
ment from the American Heart Association Councils on Kidney in
Cardiovascular Disease, High Blood Pressure Research, Clini-
cal Cardiology, and Epidemiology and Prevention. Circulation
108:2154–2169, 2003
7. HAFFNER SM, LEHTO S, RONNEMAA T, et al: Mortality from coronary
heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction. N Engl J
Med 339:229–234, 1998
8. VASAN RS, SULLIVAN LM, ROUBENOFF R, et al: Inflammatory markers
and risk of heart failure in elderly subjects without prior myocar-
dial infarction: The Framingham Heart Study. Circulation 107:1486–
1491, 2003
9. RODBY RA, ROHDE RD, CLARKE WR et al, FOR THE COLLABORA-
TIVE STUDY GROUP. The Irbesartan Type II Diabetic Nephropathy
Trial: Study design and baseline patient characteristics. Nephrol Dial
Transplant 15:487–497, 2000.
10. LEWIS EJ, HUNSICKER LG, CLARKE WR et al: Renoprotective effect
of the angiotensin-receptor antagonist irbesartan in patients with
nephropathy due to type 2 diabetes. N Engl J Med 345:851–860,
2001
11. BERL T, HUNSICKER LG, LEWIS JB, et al: Cardiovascular outcomes
in the Irbesartan Diabetic Nephropathy Trial of patients with type
2 diabetes and overt nephropathy. Ann Intern Med 138:542–549,
2003
12. ANDERSON P, GILL R: Cox’s regression model for counting precesses:
A large sample study. Ann Stat 10:1100–1120, 1982
13. LEE E, WEI L, AMATO D: Cox-type regerssion analysis for large
number of small groups of correlated failure time observations, in
Survival Analysis, State of the Art, edited by Klein J, Goel P, The
Netherlands, Kluwer Academic Publishers, 1992, pp 237–247
14. GREENFIELD JR, SAMARAS K, JENKINS AB, et al: Obesity is an im-
portant determinant of baseline serum C-reactive protein concen-
tration in monozygotic twins, independent of genetic influences.
Circulation 22:3022–3028, 2004
15. ORTEGA O, RODRIGUEZ I, GALLAR P, et al: Significance of high C-
reactive protein levels in pre-dialysis patients. Nephrol Dial Trans-
plant 17:1105–1109, 2002
16. SCHULZE MB, RIMM EB, LI T, et al: C-reactive protein and inci-
dent cardiovascular events among men with diabetes. Diabetes Care
27:889–894, 2004
17. CURB JD, ABBOTT RD, RODRIGUEZ BL, et al: C-reactive protein and
the future risk of thromboembolic stroke in healthy men. Circula-
tion 107:2016–2020, 2003
18. MOJIMINIYI OA, ABDELLA N, MOUSSA MA, et al: Association of C-
reactive protein with coronary heart disease risk factors in patients
with type 2 diabetes mellitus. Diabetes Res Clin Pract 58:37–44,
2002
19. SAKKINEN P, ABBOTT RD, CURB JD, et al: C-reactive protein and
myocardial infarction. J Clin Epidemiol 55:445–451, 2002
20. DANESH J, WHEELER JG, HIRSCHFIELD GM, et al: C-reactive protein
and other circulating markers of inflammation in the prediction of
coronary heart disease. N Engl J Med 350:1387–1397, 2004
21. TALL AR: C-reactive protein reassessed. N Engl J Med 350:1450–
1452, 2004
22. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med 345:861–869, 2001
778 Friedman et al: CRP and cardiovascular outcomes in diabetic nephropathy
23. FRIEDMAN AN, HUNSICKER LG, SELHUB J, et al: Clinical and nutri-
tional correlates of C-reactive protein in type 2 diabetic nephropa-
thy. Atherosclerosis 172:121–125, 2004
24. FRIEDMAN AN, BOSTOM AG, SELHUB J, et al: The kidney and
homocysteine metabolism. J Am Soc Nephrol 12:2181–2189,
2001
25. CASTANEDA C, GORDON PL, PARKER RC, et al: Resistance train-
ing to reduce the malnutrition-inflammation complex syndrome of
chronic kidney disease. Am J Kidney Dis 43:607–616, 2004
26. RIDKER PM, RIFAI N, PFEFFER MA, et al: Long-term effects of
pravastatin on plasma concentration of C-reactive protein. The
Cholesterol and Recurrent Events (CARE) Investigators. Circu-
lation 100:230–235, 1999
27. BAUMGARTEN G, KNUEFERMANN P, MANN DL: Cytokines as emerg-
ing targets in the treatment of heart failure. Trends Cardiovasc Med
10:216–223, 2000
